<DOC>
	<DOCNO>NCT01242774</DOCNO>
	<brief_summary>This study conduct assess maximum tolerate dose ( MTD ) panobinostat give 3 time week ( administered week 2 3 4 week cycle ) combination induction chemotherapy ( idarubicin cytarabine ) newly diagnose patient cytopathologically confirm diagnosis high-risk AML , investigate safety combination regimen .</brief_summary>
	<brief_title>Safety &amp; Efficacy Study Oral Panobinostat ( LBH589 ) With Chemotherapy Patients &lt; 65 Years Old With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Newly diagnose adult patient = 65 year old cytopathologically confirm diagnosis highrisk AML = 20 % bone marrow blast via bone marrow aspiration biopsy The patient yet treat AML 1ยบ 2ยบ AML patient highrisk category feature ECOG PS = 2 Renal function liver function limit . Patient 'favorable ' 'betterrisk ' cytogenetic profile = ( 15 ; 17 ) ; ( 8 ; 21 ) ; inv ( 16 ) ( 16 ; 16 ) Patient clinical symptom suggestive CNS leukemia and/or CSF finding CNS leukemia Prior treatment deacetylase inhibitor ( DACi ) include , panobinostat Impaired cardiac function Female patient pregnant breast feed Male patient willing use barrier method contraception Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>AML</keyword>
	<keyword>bone marrow</keyword>
	<keyword>abnormal blast cell myeloid</keyword>
	<keyword>acute leukemia</keyword>
	<keyword>cytogenetic abnormality</keyword>
	<keyword>HDACi</keyword>
</DOC>